Celularity (CELU) AI Stock Analysis

• Market Cap: $37.59M
• Dividend Yield: N/A
• Average Volume (3M): 206.82K
• Price to Earnings (P/E): ―
• Beta (1Y): 3.42
• Revenue Growth: -15.81%
• EPS Growth: -113.06%
• Country: US
• Employees: 120
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.02
• Shares Outstanding: 28,478,880
• 10 Day Avg. Volume: 277,262
• 30 Day Avg. Volume: 206,824
• PEG Ratio: 0.01
• Price to Book (P/B): 5.15
• Price to Sales (P/S): 0.84
• P/FCF Ratio: -6.94
• Enterprise Value/Market Cap: 3.10
• Enterprise Value/Revenue: 2.87
• Enterprise Value/Gross Profit: 5.19
• Enterprise Value/Ebitda: -1.83
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 38 Underperform
• Price Target: $1.00 ▼(-20.00% Downside)

Celularity's overall stock score is primarily impacted by its financial instability, with high leverage and ongoing losses. Technical indicators suggest bearish momentum, and valuation metrics are weak due to negative earnings. Corporate events add further risk with shareholder resistance and regulatory challenges.

Positive Factors

Revenue Growth

Significant revenue growth indicates strong demand for Celularity's products, enhancing its market position and potential for future profitability.

Gross Margin Improvement

Improved gross margins reflect operational efficiency and cost management, which can support long-term financial health and competitiveness.

Strategic Financing

New financing enhances liquidity, enabling strategic shifts and potential growth in longevity and performance optimization sectors.

Negative Factors

High Leverage

High leverage increases financial risk, potentially limiting flexibility and increasing vulnerability to economic downturns.

Unprofitability

Ongoing unprofitability suggests challenges in covering operational costs, which could hinder long-term sustainability and investor confidence.

Regulatory Challenges

FDA warning highlights regulatory compliance issues, which could affect reputation and require resource allocation to address compliance.

Celularity Business Overview & Revenue Model

Company Description

Celularity Inc. is a biotechnology company focused on developing innovative cell-based therapies for the treatment of cancer, degenerative diseases, and other serious conditions. The company leverages its proprietary platform that utilizes placental-derived cells, particularly those from the human placenta, to create advanced therapeutic products. Celularity operates primarily within the sectors of regenerative medicine and immunotherapy, aiming to harness the unique properties of these cells to improve patient outcomes.

How the Company Makes Money

Celularity generates revenue through multiple streams, primarily from the commercialization of its cell therapies and related products. This includes sales of its therapeutic offerings directly to healthcare providers and hospitals. Additionally, the company may engage in partnerships with pharmaceutical firms for co-development and licensing of its technologies, which can provide upfront payments, milestone payments, and royalties on future sales. Research grants and funding from governmental and non-governmental organizations focused on advancing regenerative medicine also contribute to their financial resources. Moreover, Celularity may explore collaborations with academic institutions and other biotech companies to enhance its research capabilities and expand its product pipeline, further driving future revenue potential.

Celularity Financial Statement Overview

Summary

Celularity shows strong revenue growth but remains unprofitable with high operational expenses. The balance sheet indicates high leverage and declining equity, raising financial stability concerns. Cash flows are negative but improving, supported by financing activities.

Income Statement

Celularity has shown a significant increase in revenue, growing from $22.8 million in 2023 to $54.2 million in 2024. However, the company remains unprofitable with a negative net profit margin due to high operational expenses, as indicated by negative EBIT and EBITDA margins. The gross profit margin improved to 83.6% in 2024 from 29.7% in 2023, which is a positive sign of operational efficiency.

Balance Sheet

The balance sheet reveals high leverage with a debt-to-equity ratio of 3.29 in 2024, indicating financial risk. The equity ratio is low at 6.7%, showing limited equity buffer. The stockholders' equity has decreased significantly, reflecting potential financial instability and risk.

Cash Flow

Celularity's free cash flow remains negative, but has improved from -$42.7 million in 2023 to -$6.56 million in 2024. The operating cash flow to net income ratio is negative, highlighting ongoing cash drain. However, the company successfully raised funds through financing activities, providing some liquidity cushion.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	40.58M	54.22M	22.77M	17.98M	21.34M	14.28M
Gross Profit	22.42M	39.23M	6.75M	-1.69M	11.68M	9.35M
EBITDA	-63.56M	-43.71M	-183.95M	-138.83M	-88.11M	-202.41M
Net Income	-80.64M	-57.89M	-196.29M	14.19M	-100.12M	-208.23M
Balance Sheet
Total Assets	114.24M	132.68M	143.89M	401.07M	414.13M	431.01M
Cash, Cash Equivalents and Short-Term Investments	120.00K	738.00K	227.00K	13.97M	37.24M	54.31M
Total Debt	66.76M	68.84M	65.42M	65.59M	31.14M	30.64M
Total Liabilities	134.33M	123.84M	102.93M	202.16M	314.71M	412.30M
Stockholders Equity	-20.09M	8.84M	40.96M	198.90M	99.42M	18.71M
Cash Flow
Free Cash Flow	-6.61M	-6.56M	-42.73M	-143.11M	-116.30M	-91.03M
Operating Cash Flow	-6.56M	-6.40M	-38.69M	-137.88M	-110.10M	-63.19M
Investing Cash Flow	-1.56M	514.00K	-4.05M	-5.24M	-5.90M	-12.81M
Financing Cash Flow	8.07M	6.70M	24.09M	119.84M	98.56M	102.01M

Celularity Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.25
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CELU, the sentiment is Negative. The current price of 1.25 is below the 20-day moving average (MA) of 1.67, below the 50-day MA of 1.78, and below the 200-day MA of 2.13, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 34.02 is Neutral, neither overbought nor oversold. The STOCH value of 11.59 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CELU.

Celularity Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RPTX	60 Neutral	$109.93M	-1.51	-49.78%	―	-82.16%	14.58%
STTK	54 Neutral	$207.56M	-3.22	-57.84%	―	-84.46%	33.32%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LTRN	45 Neutral	$37.36M	-1.91	-104.58%	―	―	1.18%
GBIO	39 Underperform	$37.46M	-0.59	-80.81%	―	-17.82%	57.32%
CELU	38 Underperform	$37.59M	-0.40	―	―	-15.81%	-113.06%
FBLG	38 Underperform	$17.71M	-0.49	-1292.87%	―	―	18.47%

Celularity Corporate Events

Celularity Shareholders Reject Expansion of Equity Incentive Plan

Celularity Inc. held its Annual Meeting of Stockholders on December 19, 2025, where shareholders voted on director elections, auditor ratification and a proposed amendment to the company’s equity incentive plan. Stockholders reelected three Class I directors to serve until 2028 and ratified the appointment of EisnerAmper LLP as independent auditor for the 2025 fiscal year, but they rejected a proposal to increase the share reserve under the 2021 Equity Incentive Plan by 3.5 million shares, signaling shareholder resistance to further equity-based dilution and potentially constraining the company’s use of stock compensation going forward.

Celularity Receives FDA Warning Over Marketing Claims

On December 1, 2025, Celularity Inc. received a warning letter from the FDA concerning the marketing materials for Interfyl, a human connective tissue matrix. The letter emphasized the need to limit outcome-based claims and metabolic activity descriptions in marketing to comply with regulatory standards. Despite the warning, the company’s manufacturing and shipping operations remain unaffected, and no product recalls are required. Celularity is actively engaging with the FDA to address the issues, although there is no assurance of a swift resolution. The company does not anticipate any material impact on its operational or financial expectations due to the letter.

Celularity Secures $2 Million in Private Placement

On October 24, 2025, Celularity Inc. entered into a Securities Purchase Agreement with an institutional investor to issue and sell Series A Convertible Preferred Stock and accompanying warrants in a private placement transaction. The initial tranche closed on the same day, providing the company with approximately $2 million in gross proceeds. The funds are intended for working capital and general corporate purposes, potentially impacting the company’s financial flexibility and market operations. The agreement includes provisions for conversion, voting rights, and dividend entitlements, with implications for shareholder equity and market positioning.